The Use of Inhaled Epoprostenol for Acute Respiratory Distress Syndrome Secondary due to COVID-19: A Case Series

1[Internet]. . Who.int. 2020 [cited 2020 Jun 25]. Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200608-covid-19-sitrep-140.pdf?sfvrsn=2f310900_2[Internet]. Who.int. 2020 [cited 2020 Jun 25] Available from https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200608-covid-19-sitrep-140.pdf?sfvrsn=2f310900_2Search in Google Scholar

2Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020;8(5):475-481.Yang X Yu Y Xu J et al Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study Lancet Respir Med 20208 5 475 48110.1016/S2213-2600(20)30079-5Search in Google Scholar

3Cummings M, Baldwin M, Abrams D, et al. Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study. Lancet. 2020;395(10239):1763-1770.Cummings M Baldwin M Abrams D et al Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study Lancet 2020395 10239 1763 177010.1016/S0140-6736(20)31189-2Search in Google Scholar

4Bhatraju P, Ghassemieh B, Nichols M, et al. Covid-19 in Critically Ill Patients in the Seatle Region — Case Series. N Engl J Med. 2020;382(21):2012-2022.Bhatraju P Ghassemieh B Nichols M et al Covid-19 in Critically Ill Patients in the Seatle Region — Case Series N Engl J Med 2020382 21 2012 202210.1056/NEJMoa2004500714316432227758Search in Google Scholar

5Berlin DA, Gulick RM, Martinez FJ Severe Covid-19. Published online May 15th, 2020 DOI: https://doi.org/10.1056/NEJMcp2009575Berlin DA Gulick RM Martinez FJ Severe Covid-19 Published online May 15th 2020 https://doi.org/10.1056/NEJMcp200957510.1056/NEJMcp200957532412710Search in Google Scholar

6Tabrizi M, Schinco M, Tepas J, et al. Inhaled epoprostenol improves oxygenation in severe hypoxemia. J Trauma Acute Care Surg. 2012;73(2):503-506.Tabrizi M Schinco M Tepas J et al Inhaled epoprostenol improves oxygenation in severe hypoxemia J Trauma Acute Care Surg 201273 2 503 50610.1097/TA.0b013e318258431e23019678Search in Google Scholar

7Alessandri F, Pugliese F, Ranieri V. The Role of Rescue Therapies in the Treatment of Severe ARDS. Respir Care. 2017;63(1):92101.Alessandri F Pugliese F Ranieri V The Role of Rescue Therapies in the Treatment of Severe ARDS Respir Care 201763 1 9210110.4187/respcare.0575229066591Search in Google Scholar

8Duan E, Adhikari N, D’Aragon F, et al. Management of Acute Respiratory Distress Syndrome and Refractory Hypoxemia. A Multicenter Observational Study. Ann Am Thorac Soc. 2017;14(12):1818-1826.Duan E Adhikari N D’Aragon F et al Management of Acute Respiratory Distress Syndrome and Refractory Hypoxemia A Multicenter Observational Study. Ann Am Thorac Soc 201714 12 1818 182610.1513/AnnalsATS.201612-1042OC28910146Search in Google Scholar

9Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome. N Engl J Med. 2000;342(18):1301-1308.Ventilation with Lower Tidal Volumes as Compared with Traditional Tidal Volumes for Acute Lung Injury and the Acute Respiratory Distress Syndrome N Engl J Med 2000342 18 1301 130810.1056/NEJM20000504342180110793162Search in Google Scholar

10Wiedemann H, Wheeler A, Bernard G. Comparison of two fluid-management strategies in acute lung injury. J Vasc Surg. 2006;44(4):909.Wiedemann H Wheeler A Bernard G Comparison of two fluid-management strategies in acute lung injury J Vasc Surg 200644 4 90910.1016/j.jvs.2006.08.053Search in Google Scholar

11Briel M, Meade M, Mercat A, et al. Higher versus lower positive end-expiratory pressure in acute lung injury and acute respiratory distress syndrome: systematic review and individual patient data meta-analysis. Crit Care. 2010;14(Suppl 1): P182.Briel M Meade M Mercat A et al Higher versus lower positive end-expiratory pressure in acute lung injury and acute respiratory distress syndrome: systematic review and individual patient data meta-analysis Crit Care 201014 Suppl 1 P18210.1186/cc8414Search in Google Scholar

12Alhazzani W, Møller M, Arabi Y, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020;48(6):e440-e469.Alhazzani W Møller M Arabi Y et al Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19) Crit Care Med 202048 6 e440 e46910.1097/CCM.0000000000004363717626432224769Search in Google Scholar

13Fuller B, Mohr N, Skrupky L, Fowler S, Kollef M, Carpenter C. The Use of Inhaled Prostaglandins in Patients With ARDS. Chest. 2015;147(6):1510-1522.Fuller B Mohr N Skrupky L Fowler S Kollef M Carpenter C The Use of Inhaled Prostaglandins in Patients With ARDS Chest 2015147 6 1510 152210.1378/chest.14-3161445170725742022Search in Google Scholar

14Dzierba A, Abel E, Buckley M, Lat I. A Review of Inhaled Nitric Oxide and Aerosolized Epoprostenol in Acute Lung Injury or Acute Respiratory Distress Syndrome. Pharmacotherapy. 2013;34(3):279-290.Dzierba A Abel E Buckley M Lat I A Review of Inhaled Nitric Oxide and Aerosolized Epoprostenol in Acute Lung Injury or Acute Respiratory Distress Syndrome Pharmacotherapy 201334 3 279 29010.1002/phar.136524734313Search in Google Scholar

15Torbic H, Szumita P, Anger K, et al. Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients. J Crit Care. 2013;28(5):844-848.Torbic H Szumita P Anger K et al Inhaled epoprostenol vs inhaled nitric oxide for refractory hypoxemia in critically ill patients J Crit Care 201328 5 844 84810.1016/j.jcrc.2013.03.00623683572Search in Google Scholar

16Searcy R, Morales J, Ferreira J, Johnson D. The role of inhaled prostacyclin in treating acute respiratory distress syndrome. Ther Adv in Respir Dis. 2015;9(6):302-312.Searcy R Morales J Ferreira J Johnson D The role of inhaled prostacyclin in treating acute respiratory distress syndrome Ther Adv in Respir Dis 20159 6 302 31210.1177/175346581559934526294418Search in Google Scholar

17Dellinger R, Zimmerman J, Taylor R, et al. Efects of inhaled nitric oxide in patients with acute respiratory distress syndrome. Crit Care Med. 1998;26(1):15-23.Dellinger R Zimmerman J Taylor R et al Efects of inhaled nitric oxide in patients with acute respiratory distress syndrome Crit Care Med 199826 1 15 2310.1097/00003246-199801000-000119428538Search in Google Scholar

18Fallah F. Recent Strategies in Treatment of Pulmonary Arterial Hypertension, A Review. Glob J of Health Sci. 2015Jan25;7(4).Fallah F Recent Strategies in Treatment of Pulmonary Arterial Hypertension, A Review Glob J of Health Sci 2015 Jan257 410.5539/gjhs.v7n4p307480218325946920Search in Google Scholar

19De Wet CJ, Afleck DG, Jacobsohn E, et al. Inhaled prostacyclin is safe, efective, and afordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery. J Thorac Cardiovasc Surg. 2004;127(4):1058–67.De Wet CJ Afleck DG Jacobsohn E et al Inhaled prostacyclin is safe, efective, and afordable in patients with pulmonary hypertension, right heart dysfunction, and refractory hypoxemia after cardiothoracic surgery J Thorac Cardiovasc Surg 2004127 4 1058 6710.1016/j.jtcvs.2003.11.03515052203Search in Google Scholar

20Epoprostenol [package insert]. . Federal Drug Administration: GlaxoSmithKline; 1995.Epoprostenol [package insert] Federal Drug Administration: GlaxoSmithKline; 1995Search in Google Scholar

21Liu X, Wang X-J. Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines. J Genet Genomics. 2020:20;47(2):119-121.Liu X Wang X-J Potential inhibitors for 2019-nCoV coronavirus M protease from clinically approved medicines J Genet Genomics 20202047 2 119 12110.1101/2020.01.29.924100Search in Google Scholar

22Rismanbaf A. Potential Treatments for COVID-19; a Narrative Literature Review. Arch Acad Emerg Med. 2020;8(1).Rismanbaf A Potential Treatments for COVID-19; a Narrative Literature Review Arch Acad Emerg Med 20208 1Search in Google Scholar

23Farag A, Wang P, Ahmed M, Sadek H. Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning (Version 2). ChemRxiv. Published online 2020; DOI: doi.org/10.26434/chemrxiv.12003930.v2Farag A Wang P Ahmed M Sadek H Identification of FDA Approved Drugs Targeting COVID-19 Virus by Structure-Based Drug Repositioning (Version 2). ChemRxiv Published online 2020 doi.org/10.26434/chemrxiv.12003930.v2Open DOISearch in Google Scholar

24COVID View, Key Updates for Week 22 [Internet]. Centers for Disease Control and Prevention. 2020 [accessed 2020 June 7th]. Available from: https://www.cdc.gov/coronavirus/2019ncov/covid-data/covidview/index.htmlCOVID View Key Updates for Week 22 [Internet] Centers for Disease Control and Prevention 2020 [accessed 2020 June 7th]. Available from https://www.cdc.gov/coronavirus/2019ncov/covid-data/covidview/index.htmlSearch in Google Scholar

25Feng Y, Amoateng-Adjepong Y, Kaufman D, Gheorghe C, Manthous C. Age, Duration of Mechanical Ventilation, and Outcomes of Patients Who Are Critically Ill. Chest. 2009;136(3):759-764.Feng Y Amoateng-Adjepong Y Kaufman D Gheorghe C Manthous C Age, Duration of Mechanical Ventilation, and Outcomes of Patients Who Are Critically Ill Chest 2009136 3 759 76410.1378/chest.09-051519736189Search in Google Scholar

26Ware L, Mathay M. The Acute Respiratory Distress Syndrome. N Engl J Med. 2000;342(18):1334-1349.Ware L Mathay M The Acute Respiratory Distress Syndrome N Engl J Med 2000342 18 1334 134910.1056/NEJM20000504342180610793167Search in Google Scholar

27Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admited to ICUs of the Lombardy Region, Italy. JAMA. 2020;323(16):1574.Grasselli G Zangrillo A Zanella A et al Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admited to ICUs of the Lombardy Region, Italy JAMA 2020323 16 157410.1001/jama.2020.5394713685532250385Search in Google Scholar

28Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med. 1996;154(6):16711677.Zwissler B Kemming G Habler O et al Inhaled prostacyclin (PGI2) versus inhaled nitric oxide in adult respiratory distress syndrome Am J Respir Crit Care Med 1996154 6 1671167710.1164/ajrccm.154.6.89703538970353Search in Google Scholar

29Bernard G, Artigas A, Brigham K, et al. Report of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination. Intensive Care Med. 1994;20(3):225-232.Bernard G Artigas A Brigham K et al Report of the American-European consensus conference on ARDS: Definitions, mechanisms, relevant outcomes and clinical trial coordination Intensive Care Med 199420 3 225 23210.1007/BF017047078014293Search in Google Scholar

30DeGrado J, Szumita PM, Schuler BR, et al. Evaluation of the Eficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients with Coronavirus Disease 2019. Crit Care Explore. 2020;2(10):e0259DeGrado J Szumita PM Schuler BR et al Evaluation of the Eficacy and Safety of Inhaled Epoprostenol and Inhaled Nitric Oxide for Refractory Hypoxemia in Patients with Coronavirus Disease 2019 Crit Care Explore 20202 10 e025910.1097/CCE.0000000000000259758106633134949Search in Google Scholar

31Sonti R, Pike CW, Cobb N. Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19. J Intensive Care Med. 2021;36(3):327-333.Sonti R Pike CW Cobb N Responsiveness of Inhaled Epoprostenol in Respiratory Failure due to COVID-19 J Intensive Care Med 202136 3 327 33310.1177/0885066620976525772425333234007Search in Google Scholar